Lisa A Carey MD

Oncology•Chapel Hill, NC

Professor of Hematology & Oncology, University of North Carolina School of Medicine

Join to View Full Profile

101 Manning DrChapel Hill, NC 27514
Phone+1 919-966-4996
Fax+1 919-843-5515

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1997
Johns Hopkins UniversityResidency, Internal Medicine, 1990 - 1993
Johns Hopkins University School of MedicineClass of 1990

Certifications & Licensure

NC State Medical License 1997 - 2026
MD State Medical License 1993 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Start of enrollment: 1998 Dec 01
Completed
Phase 2
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 2
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Start of enrollment: 2008 Jun 18
Completed
Phase 2
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
ACTIVE_NOT_RECRUITING
PHASE2
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior Start of enrollment: 1998 Dec 01
RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 Start of enrollment: 2012 Jan 01
Completed
Early Phase 1
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib Start of enrollment: 2013 Aug 05
Completed
Early Phase 1
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Start of enrollment: 2014 Jan 30
ACTIVE_NOT_RECRUITING
PHASE2
The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer Start of enrollment: 2014 Mar 01
Completed
The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PE...
Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil, Christoph Zielinski, Manuel Ruiz-Borrego
JCO Precision Oncology. 2025-07-01
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.
Eric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, Matthew V Holt, LaTerrica Williams
Cell Reports. Medicine. 2025-06-17
2 citations
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.
Wolfgang Janni, Thomas W P Friedl, Tracy C Yab, Francois-Clément Bidard, Massimo Cristofanilli
Clinical Cancer Research. 2025-06-03

Journal Articles

Integrated Analysis of RNA and DNA from a Phase III Trial of Trastuzumab-Based Neoadjuvant Chemotherapy Identifies Response Predictors in HER2-Positive Breast Cancer
Lisa Carey, MD, Clinical Cancer Research

Lectures

HER2-Targeted Therapy: Changing the Story of Breast Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Authored Content

Key Immunotherapy Presentations in Early Breast Cancer from ESMO 2023: KEYNOTE-756, CheckMate-7FL, and Updated KEYNOTE-522October 2023
Endocrine-Based Therapy for Early and Metastatic Breast Cancer: New Horizons from ASCO 2023June 2023

Press Mentions

UNC Cancer Center Awarded $28M to Lead ‘Adaptive’ Clinical TrialAugust 11th, 2025
Researchers Aim to Adapt Metastatic Breast Cancer Therapy as Tumors ChangeJuly 2nd, 2025
UNC’s Lineberger Cancer Center Awarded $28 Million for New Clinical TrialJune 21st, 2025
Join now to see all

Grant Support

SPORE in Breast CancerUNIV OF NORTH CAROLINA CHAPEL HILL1997–2029
SPORE in Breast CancerUNIV OF NORTH CAROLINA CHAPEL HILL1997–2029
UNC Lead Academic Participating SiteUNIV OF NORTH CAROLINA CHAPEL HILL2019–2026
UNC Lead Academic Participating SiteUNIV OF NORTH CAROLINA CHAPEL HILL2019–2025
Optimizing HER2-targeting using RNA- and DNA-based predictive algorithmsUNIV OF NORTH CAROLINA CHAPEL HILL2019–2025
Breast Cancer ResearchNational Cancer Institute2011–2012
Academic Training In Oncology At The University Of North Carolina At Chapel HillNational Cancer Institute2011
Lccc 0403: Phase II Cetuximab Alone And In Combination With CarboplatinNational Center For Research Resources2007
Lccc 9818: Stage IIB, Stage IIIA/B Stage IV Breast CancerNational Center For Research Resources2004–2006
Tamoxifen &Raloxifene For Preventtion Of Breast CancerNational Center For Research Resources2000
Molecular Markers W/ Response To Chemotherapy In Breast CANational Center For Research Resources2000
Doxorubicin &Cyclophosphamide &Paclitaxel W/ HerceptinNational Center For Research Resources2000